Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registrydata

ConclusionsThese findings demonstrated that only a small fraction of eligible patients underwent IP/IV chemotherapy. We report a significant 10 ‐year survival, but not necessarily recurrence benefit is associated with IP/IV chemotherapy compared to IV only, suggesting the need for novel ways of identifying patients who may benefit from IP/IV chemotherapy.

Source: Cancer Medicine - August 18, 2020 Category: Cancer & Oncology Authors: Shalkar Adambekov, Samia Lopa, Robert P. Edwards, Lara Lemon, Shu Wang, Sarah E. Taylor, Brian Orr, Faina Linkov Tags: ORIGINAL RESEARCH Source Type: research